• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一位患有“好综合征”患者胸腺瘤与可溶性白细胞介素-2受体表达之间的相关性

Correlation Between Thymoma and Soluble Interleukin-2 Receptor Expression in a Patient with Good Syndrome.

作者信息

Kitano Haruka, Yamaguchi Fumihiro, Atarashi Kenji, Hiraiwa Mina, Shiratori Yo, Onozaki Shota, Shikama Yusuke

机构信息

Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, 227-8501, Japan.

出版信息

Onco Targets Ther. 2021 Oct 12;14:5045-5049. doi: 10.2147/OTT.S326193. eCollection 2021.

DOI:10.2147/OTT.S326193
PMID:34675549
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8520479/
Abstract

Good syndrome is a rare condition characterized by the presence of thymoma in combination with adult-onset hypogammaglobulinemia. Immunological features of Good syndrome include various immunodeficiencies accompanied with hypogammaglobulinemia. In patients with thymoma, paraneoplastic syndromes including hypogammaglobulinemia worsen the prognosis. We herein describe a patient with advanced-stage type A thymoma who was effectively treated with chemotherapy and exhibited a parallel decrease in the serum level of soluble interleukin-2 receptor (sIL-2R), which depends on cellular immunity. The present case suggests the efficacy of sIL-2R as a potential prognostic biomarker in a subset of patients with Good syndrome.

摘要

古德综合征是一种罕见病症，其特征为胸腺瘤合并成人期低丙种球蛋白血症。古德综合征的免疫学特征包括各种免疫缺陷并伴有低丙种球蛋白血症。在胸腺瘤患者中，包括低丙种球蛋白血症在内的副肿瘤综合征会使预后恶化。我们在此描述一名晚期A型胸腺瘤患者，该患者接受化疗后得到有效治疗，且其依赖细胞免疫的可溶性白细胞介素-2受体（sIL-2R）血清水平出现相应下降。本病例提示sIL-2R作为古德综合征部分患者潜在预后生物标志物的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/cec852062215/OTT-14-5045-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/163739a91641/OTT-14-5045-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/6ac4c49efce2/OTT-14-5045-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/aa2cba68341f/OTT-14-5045-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/cec852062215/OTT-14-5045-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/163739a91641/OTT-14-5045-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/6ac4c49efce2/OTT-14-5045-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/aa2cba68341f/OTT-14-5045-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/8520479/cec852062215/OTT-14-5045-g0004.jpg

相似文献

1
Correlation Between Thymoma and Soluble Interleukin-2 Receptor Expression in a Patient with Good Syndrome.一位患有“好综合征”患者胸腺瘤与可溶性白细胞介素-2受体表达之间的相关性
Onco Targets Ther. 2021 Oct 12;14:5045-5049. doi: 10.2147/OTT.S326193. eCollection 2021.
2
Is hypogammaglobulinemia a constant feature in Good's syndrome?低丙种球蛋白血症是否是 Good 综合征的一个固有特征？
Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1275-9. doi: 10.1177/039463201002300434.
3
Durable hypogammaglobulinemia associated with thymoma (Good syndrome).与胸腺瘤相关的持续性低丙种球蛋白血症（古德综合征）。
Intern Med. 2009;48(19):1749-52. doi: 10.2169/internalmedicine.48.2375. Epub 2009 Oct 1.
4
Immunodeficiency and thymoma in Good syndrome: Two sides of the same coin.Good 综合征伴免疫缺陷和胸腺瘤：同一问题的两个方面。
Immunol Lett. 2021 Mar;231:11-17. doi: 10.1016/j.imlet.2020.12.010. Epub 2021 Jan 5.
5
Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.侵袭性非霍奇金淋巴瘤患者血清中可溶性白细胞介素-2受体和白细胞介素-10的检测。识别治疗失败高风险亚组。
Cancer. 1994 Sep 15;74(6):1792-800. doi: 10.1002/1097-0142(19940915)74:6<1792::aid-cncr2820740623>3.0.co;2-f.
6
Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.血清可溶性白细胞介素-2受体（sIL-2R）水平可决定侵袭性非霍奇金淋巴瘤患者的临床结局：与国际预后指数相结合。
J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9. doi: 10.1007/s00432-004-0600-9. Epub 2004 Oct 21.
7
[Thymoma with immunodeficiency/Good syndrome associated with myasthenia gravis].[胸腺瘤伴免疫缺陷/古德综合征合并重症肌无力]
Rinsho Shinkeigaku. 2017 May 27;57(5):208-213. doi: 10.5692/clinicalneurol.cn-000984. Epub 2017 Apr 27.
8
Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review.可溶性白细胞介素-2受体在噬血细胞综合征中的临床应用：一项系统综述。
Ann Hematol. 2017 Aug;96(8):1241-1251. doi: 10.1007/s00277-017-2993-y. Epub 2017 May 12.
9
Thymoma associated with hypogammaglobulinemia (Good's syndrome): report of a case.胸腺瘤合并低丙种球蛋白血症（古德综合征）：一例报告。
Surg Today. 2002;32(3):264-6. doi: 10.1007/s005950200032.
10
High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.血清可溶性白细胞介素-2 受体水平高与未经特殊说明的首次复发或难治性外周 T 细胞淋巴瘤患者的不良生存相关：一项回顾性研究。
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e337-e342. doi: 10.1016/j.clml.2019.03.031. Epub 2019 Apr 5.

本文引用的文献

1
Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.血清可溶性白细胞介素-2 受体作为免疫相关不良事件的潜在生物标志物。
Anticancer Res. 2021 Feb;41(2):1021-1026. doi: 10.21873/anticanres.14857.
2
Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions.血清可溶性白细胞介素-2受体水平用于恶性淋巴瘤的筛查及与其他疾病的鉴别诊断。
Mol Clin Oncol. 2019 Nov;11(5):474-482. doi: 10.3892/mco.2019.1922. Epub 2019 Sep 11.
3
Acquired immunodeficiency associated with thymoma: a case report.
获得性免疫缺陷相关胸腺瘤：一例报告。
BMC Cancer. 2019 Aug 2;19(1):762. doi: 10.1186/s12885-019-5980-y.
4
Systemic treatments for thymoma and thymic carcinoma: A systematic review.胸腺瘤和胸腺癌的系统治疗：系统评价。
Lung Cancer. 2018 Dec;126:25-31. doi: 10.1016/j.lungcan.2018.10.018. Epub 2018 Oct 18.
5
High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy.可溶性白细胞介素-2受体的高预处理水平是接受R-CHOP样治疗的滤泡性淋巴瘤患者的一个有力预后因素。
Blood Cancer J. 2017 Sep 29;7(9):e614. doi: 10.1038/bcj.2017.96.
6
A 66-Year-Old Man With Mediastinal Mass and Dyspnea.一位 66 岁男性，因纵隔肿块伴呼吸困难就诊。
Chest. 2016 Oct;150(4):e109-e115. doi: 10.1016/j.chest.2016.07.002.
7
Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective.“好综合征”的预后：胸腺oma相关免疫缺陷的死亡率和发病率展望
Clin Immunol. 2016 Oct;171:12-17. doi: 10.1016/j.clim.2016.07.025. Epub 2016 Aug 4.
8
Thymoma and thymic carcinomas.胸腺瘤和胸腺癌。
Crit Rev Oncol Hematol. 2016 Mar;99:332-50. doi: 10.1016/j.critrevonc.2016.01.012. Epub 2016 Jan 19.
9
Good syndrome, bad problem.综合征虽好，但问题棘手。
Front Oncol. 2014 Nov 10;4:307. doi: 10.3389/fonc.2014.00307. eCollection 2014.
10
Three difficult cases: the challenge of autoimmunity, immunodeficiency and recurrent infections in patients with Good syndrome.三种疑难病例：Good 综合征患者自身免疫、免疫缺陷和反复感染的挑战。
Br J Dermatol. 2015 Mar;172(3):774-7. doi: 10.1111/bjd.13293. Epub 2015 Feb 5.